1月26日，新天地涨1.39%，成交额6841.14万元。两融数据显示，当日新天地获融资买入额831.49万 元，融资偿还618.14万元，融资净买入213.36万元。截至1月26日，新天地融资融券余额合计9541.66万 元。 融资方面，新天地当日融资买入831.49万元。当前融资余额9541.66万元，占流通市值的1.86%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，新天地1月26日融券偿还3500.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，新天地药业股份有限公司位于河南省长葛市魏武路南段东侧，成立日期2005年9月15日，上 市日期2022年11月16日，公司主营业务涉及手性医药中间体的研发、生产和销售。主营业务收入构成 为：左旋对羟基苯甘氨酸系列产品83.74%，对甲苯磺酸14.78%，其他(补充)1.49%。 截至12月19日，新天地股东户数1.79万，较上期减少2.02%；人均流通股21856股，较上期增加2.06%。 2025年1月-9月，新天地实现营业收入4.81 ...

证券日报网讯 1月26日，新天地在互动平台回答投资者提问时表示，公司医药中间体业务主要产品包括 左旋对羟基苯甘氨酸系列产品和对甲苯磺酸系列产品。左旋对羟基苯甘氨酸系列产品主要用于合成阿莫 西林、头孢羟氨苄、头孢哌酮等抗感染类原料药。公司为国内主要对甲苯磺酸生产企业，拥有该产品从 低含量到高含量多规格品种生产能力，客户覆盖医药、建材、高端铸造、电子化学、印染、电池等行 业；医药级对甲苯磺酸作为催化剂在化学合成中广泛使用，也作为中间体用于合成部分抗感染、抗肿 瘤、抗凝血等药物。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the articles indicates that Xintiandi's stock has shown fluctuations, with a current price of 11.94 CNY per share and a market capitalization of 4.681 billion CNY, reflecting a year-to-date increase of 24.47% [1] - The company has experienced a net inflow of main funds amounting to 21.93 thousand CNY, with significant buying and selling activities recorded [1] - Xintiandi has appeared on the trading leaderboard 14 times this year, with the most recent occurrence on June 9, where it recorded a net buy of -20.0864 million CNY [1] Group 2 - As of December 10, the number of Xintiandi shareholders decreased to 18,300, while the average circulating shares per person increased by 1.85% to 21,414 shares [2] - For the period from January to September 2025, Xintiandi reported a revenue of 481 million CNY, representing a year-on-year decrease of 10.42%, and a net profit attributable to shareholders of 91.907 million CNY, down 35.19% year-on-year [2] - Since its A-share listing, Xintiandi has distributed a total of 259 million CNY in dividends [3]

Core Points - The stock price of Xintiandi increased by 2.11% on November 14, reaching 13.53 CNY per share, with a total market capitalization of 5.305 billion CNY [1] - The company has seen a year-to-date stock price increase of 41.04%, with a recent 5-day increase of 4.88% and a 20-day increase of 4.24%, while experiencing a 6.30% decline over the past 60 days [1] - Xintiandi has appeared on the trading leaderboard 14 times this year, with the most recent appearance on June 9, where it recorded a net buy of -20.0864 million CNY [1] Financial Performance - For the period from January to September 2025, Xintiandi reported operating revenue of 481 million CNY, a year-on-year decrease of 10.42%, and a net profit attributable to shareholders of 91.9007 million CNY, down 35.19% year-on-year [2] - Since its A-share listing, Xintiandi has distributed a total of 259 million CNY in dividends [3] Shareholder Information - As of November 10, Xintiandi had 18,800 shareholders, an increase of 0.60% from the previous period, with an average of 5,374 circulating shares per shareholder, a decrease of 0.60% [2] Company Overview - Xintiandi Pharmaceutical Co., Ltd. is located in Changge City, Henan Province, and was established on September 15, 2005, with its listing date on November 16, 2022 [1] - The company's main business involves the research, development, production, and sales of chiral pharmaceutical intermediates, with the revenue composition being 83.74% from L-phenylalanine series products, 14.78% from p-toluenesulfonic acid, and 1.49% from other sources [1]

Core Viewpoint - Xintiandi is a leading supplier of chiral pharmaceutical intermediates in China, with a full industry chain advantage and product quality meeting international standards [1] Group 1: Company Overview - Xintiandi was established on September 15, 2005, and was listed on the Shenzhen Stock Exchange on November 16, 2022, with its registered and office location in Henan Province [1] - The company primarily engages in the research, development, production, and sales of chiral pharmaceutical intermediates, operating within the pharmaceutical and biological - chemical pharmaceutical - raw materials sector [1] Group 2: Financial Performance - For Q3 2025, Xintiandi reported revenue of 481 million yuan, ranking 30th among 47 companies in the industry, while the industry leader, Prolo Pharmaceutical, achieved 7.764 billion yuan [2] - The main business composition includes L-phenylalanine series products at 300 million yuan, accounting for 83.74%, and p-toluenesulfonic acid at 52.862 million yuan, accounting for 14.78% [2] - The net profit for the same period was 91.27 million yuan, ranking 20th in the industry, with the industry leader, Zhejiang Pharmaceutical, reporting 867 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, Xintiandi's debt-to-asset ratio was 12.74%, lower than the previous year's 13.12% and significantly below the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for the period was 35.86%, which, although lower than the previous year's 41.01%, remains above the industry average of 35.38% [3] Group 4: Executive Compensation - The chairman, Xie Jianzhong, received a salary of 585,400 yuan in 2024, an increase of 18,100 yuan from 2023 [4] - The general manager, Zhang Luwei, earned 488,000 yuan in 2024, up by 5,600 yuan from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.66% to 18,500, while the average number of circulating A-shares held per household increased by 0.66% to 5,448.09 [5]

Group 1 - The core viewpoint of the articles indicates that Xintiandi has experienced fluctuations in stock performance and financing activities, with a notable increase in trading volume and a significant financing balance [1][2]. - As of October 10, Xintiandi's stock price rose by 2.11%, with a trading volume of 59.40 million yuan and a net financing purchase of 1.02 million yuan [1]. - The financing balance of Xintiandi reached 104 million yuan, accounting for 7.86% of its market capitalization, which is above the 50th percentile level over the past year, indicating a high level of financing activity [1]. Group 2 - As of September 19, the number of shareholders for Xintiandi decreased by 5.20% to 18,700, while the average circulating shares per person increased by 5.48% to 5,412 shares [2]. - For the first half of 2025, Xintiandi reported a revenue of 359 million yuan, a year-on-year decrease of 9.57%, and a net profit attributable to shareholders of 78.03 million yuan, down 30.01% year-on-year [2]. Group 3 - Since its A-share listing, Xintiandi has distributed a total of 259 million yuan in dividends [3].